Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Late to the SPEC party..lol
Time for a $SPECtacle .55 +’60%
PBM and ENSC aftermarket boom
KTRA .27 + 28% moon play not bad with .32 and .50 resistances too ponder and then the moon to $3. Cancer vaccine and merger. Congresswoman involved in play.
SMFL $3.60s +’11% 200k float and Whole Foods help it longer term
Witches working this round for SOXS wasn stopped out too early (for kettle pot and broom party) week ago
GOVX $2 warrants up 2,500% .09 to .60 this premarket more room to run here with …Under the agreement, BARDA will award GeoVax up to $45M for the manufacturing of clinical materials and support for the Phase 2b study. The government will also provide around $343M for a clinical research organization to conduct the clinical trial.
NNVC AONC NNE KA ICU DECA APLD HOLO
June’s Quad Witching Options Expiration – A Volatility Haven ¦ Jeff Hirsch
The second Quadruple Witching Week of the year brings on some volatile trading with losses frequently exceeding gains. NASDAQ has the weakest record on the first trading day of the week, down 23 times in 42 years. Quad-Witching Friday is usually better, S&P 500 has been up 12 of the last 21 years, but down 6 of the last 8.
https://time-price-research-astrofin.blogspot.com/2024/06/junes-quad-witching-options-expiration.html?m=1
HOLO 1.10 + 166 look at 1.38 resistance first then 1.65-1.75 then 1.98. Resistances pretty weak should break quickly when ready
ALUR 3.55 hod 2.80 nice eye enjoy the gains as it stands 3.70- 3.80s resistance at play
ALUR 2.28 + 110% start cashing out casino chips
SLNH 6.36 +31% great June for company…June 5th CEO’s Letter to Shareholders – CEO John Belizaire shared the Company’s 2024 strategy and roadmap for profitability.
2024 Earnings Power Presentation – The Company published its updated annual Earnings Power Presentation that includes Project Dorothy 2.
Project Kati PPA – Secured 166 MW PPA with EDF Renewables and Masdar for Project Kati in Texas. Unlocks significant Hosting potential.
Financing Secured for Project Dorothy 2 - Spring Lane Capital has agreed to lead the financing round for Project Dorothy 2 with a commitment of up to $30 million. Learn more here.
Strategic Collaboration for AI Business – We launched Soluna Cloud, our new subsidiary focused on sustainable, scalable AI Cloud and hosting services in collaboration with a Leading High-Performance Computing Company
Quick Takes Video Series - CEO John Belizaire discusses “Convergence and the Power of AI”, and Soluna’s under-rated resilience. Watch here.
AMA - The Company published responses to investor questions in its monthly AMA for April. View the responses here.
Key Project Updates:
Project Dorothy 1A (25 MW, Hosting) / Project Dorothy 1B (25 MW, Prop-Mining):
Preparations for the onset of the Four Coincident Peak Program (4CP) to begin in June through September are underway. With our participation in the program, our MaestroOS software will dynamically maintain site operations compliance with ERCOT demand thresholds through the summer months to support local community needs.
Actual power consumption and uptime % continued to remain steady for the month of May and in line with month-over-month performance.
Project Dorothy 2 (50 MW):
Project schedule in the process of being finalized with the substation interconnection targeted for late fall preceding energization of the initial 16 of 48 MW aimed for by the end of 2024.
Power partner’s approval process is nearing completion.
Spring Lane’s definitive documentation is underway.
Project Sophie (25 MW, Bitcoin Hosting with Profit Share, AI Hosting):
The team responded exceptionally well, mitigating the impacts of recent tornadoes in the Kentucky region. Despite widespread outages, their efforts resulted in minimal downtime at the site.
Infrastructure optimization efforts are ongoing to prepare for the summer heat.
Infrastructure upgrades are underway to support the growth of AI Hosted Clients.
Project Kati (166 MW):
PPA agreements signed with EDF Renewables and Masdar.
Retail Electrical Provider agreements executed with Tenaska.
ERCOT planning continues to progress with final edits made on one key study.
Negotiations continue with landowners for the site land leases.
IBRX $7.31 + 17% 09:45 AM EDT,06/20/2024 (MT Newswires) -- ImmunityBio (IBRX) said Thursday that it has launched Anktiva, its immunotherapy to treat Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer, with multiple patients across the US receiving the initial commercial doses.
The US Food and Drug Administration approved Anktiva in April to treat patients with BCG-unresponsive non-muscle invasive bladder cancer with or without papillary tumors, according to ImmunityBio.
09:45 AM EDT, 06/20/2024 (MT Newswires) -- ImmunityBio (IBRX) said Thursday that it has launched Anktiva, its immunotherapy to treat Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer, with multiple patients across the US receiving the initial commercial doses.
The US Food and Drug Administration approved Anktiva in April to treat patients with BCG-unresponsive non-muscle invasive bladder cancer with or without papillary tumors, according to ImmunityBio.
ALUR 1.20 to 2 at 1.48 + 40% Jun. 20, 2024--Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced the publication of a study demonstrating an average lean mass gain of 5.6% in patients with an average weight loss of 14% at four months on the Allurion Program. Vital signs and physical activity were tracked in real-time with the Allurion App, Connected Scale, and Health Tracker, and follow-up was provided through the AI-powered Allurion Virtual Care Suite.
In the study, 571 patients across three obesity centers treated with the Allurion Program reduced their weight on average by 13.9kg from 97.9kg to 84.0kg in just four months. Over that same period, lean mass—which includes muscle mass—increased by 2.8kg on average from 49.8kg to 52.6kg.
Higher activity patients, walking more than 8,000 daily steps on average, achieved higher weight loss (15.6kg on average, from 97.7kg to 82.1kg) and gained more lean mass (increased by 2.8kg on average from 50.9kg to 53.7kg) than their lower activity counterparts who achieved a weight loss of 13.6kg on average, from 98.2kg to 84.6kg, and whose lean mass increased by 1.8kg on average, from 49.5 to 51.3kg.
All patients experienced significant reductions in body fat percentage, decreasing from 32.7% to 27.9% in just 4 months.
Previous studies evaluating body composition changes in patients treated with GLP-1s have demonstrated that lean body mass losses are common, ranging from 3-11% lean mass reductions after around a year of treatment. Importantly, these studies did not incorporate any real-time monitoring of body composition or personalized approaches to promote lean mass preservation or muscle mass gain.1,2
“Historically, weight loss has come at the expense of lean muscle mass, the maintenance of which is critical to overall health. These results demonstrate just the opposite, providing evidence that it is possible to lose significant amounts of weight while maintaining, and even increasing, lean body mass,” said Dr. Shantanu Gaur, Founder and CEO of Allurion. “We believe that this data underscores the impact of real-time monitoring of body composition and personalized recommendations through our AI-powered Virtual Care Suite. In fact, we believe that using Allurion’s AI platform with other modalities—including GLP-1s, where muscle mass loss is a significant risk—may be a promising path forward.”
Sources: 1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038. 2. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
ZAPP 3.84 start cashing in casino chips
ZAPP 3.22 + 136%
ZAPPed again $2.91HOLO 1.20 cashing out on the way up .hold 20% longer term .cost average .95 as may just be a temp run again
HOLO 1.08 those .80s paying off
Why not ? look at that government funding $400million GOVX will be in $4s when they let it go
Reverse split $2.71 keep an eye next few weeks for bottom
MGOL 1.50 + 200% cash in all
the casino chips
MGOL 1.02 + 112% ZAPP 2.02 +’48%
Boom
One 2023 TikTok, appears to show the drive-thru assistant place order after order of McDonald’s chicken nuggets on one car’s tab, despite the customers asking it to stop while laughing. Additional posts show an array of other mishaps — such as it adding strange extras, like ice cream with ketchup and butter, or picking up orders from other nearby cars.
Unnamed sources familiar with the technology told CNBC that the technology has had difficulty interpreting different accents and dialects, among other challenges affecting order accuracy.
McDonald's declined to comment about the automated order taker's accuracy. In an initial statement, IBM said that “this technology is proven to have some of the most comprehensive capabilities in the industry, fast and accurate in some of the most demanding conditions," but did not immediately respond to a request for further comment about specifics of potential challenges.
The Armonk, New York-based tech company also said that it is currently “in discussions and pilots” with several other quick-serve restaurant clients interested in the automated order taker.
According to trade publication Restaurant Business and CNBC, which obtained a memo sent to franchisees last week, the automated order technology will be shut off in McDonald's locations testing it “no later than July 26, 2024.”
Both IBM and McDonald’s maintained that, while their AI drive-thru partnership was ending, the two would continue their relationship on other projects. McDonald's said that it still plans to use many of IBM’s products across its global system.
In December, McDonald's launched a multi-year partnership with Google Cloud. In addition to moving restaurant computations from servers into the cloud, the partnership is also set to apply generative AI “across a number of key business priorities” in restaurants around the world.
Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment
GRDI 1.16 + 100% CMND 1.71 +39%
Consider that only a small percentage of Americans are aware that they can file a complaint with the CFPB to seek resolution, and fewer still know where to go on the internet to do that. If hundreds of Americans have filed a complaint, it is highly likely that there are actually thousands of complaints that have not been filed. The CFPB knows that from experience.
It’s possible that the folks at Apple are unfamiliar with the century of abuses to customers by Goldman Sachs. Key milestones include the Goldman Sachs Trading Company’s conduct in the asset bubble of 1928. The Trading Company was a closed end fund (called a trust in those days) that Goldman Sachs created and offered to the public at $104 a share, stuffed with conflicted investments while paying Goldman a hefty management fee, only to end up a few years after the 1929 stock market crash trading at a little more than a dollar.
Then there were the 2010 Senate hearings where Goldman Sachs was shown to have been allowing hedge fund titan, John Paulson, to pick subprime debt likely to fail for one of Goldman’s securitized deals. Goldman sold the product to its customers as a good investment. Paulson made approximately $1 billion shorting the deal while those on the other side of the trade lost about $1 billion, while never being advised of the hedge fund manager’s role. According to the late U.S. Senator Carl Levin, Goldman was itself shorting (betting on subprime derivative products to fail) while actively promoting these products to clients. Comedian Jon Stewart started calling Goldman Sachs “those f*!*!ing guys” during this period.
Equally notable was the 2012 incident when Greg Smith, a VP at Goldman, tendered his resignation after 12 years with the firm on the OpEd pages of the New York Times. Smith lamented on “how callously people talk about ripping their clients off. Over the last 12 months I have seen five different managing directors refer to their own clients as ‘muppets,’ ” Smith wrote. The “muppets” characterization instantly went viral with comedic internet memes, like this catchy musical video written by former Wall Street veteran and law professor Frank Partnoy.
More recently, Goldman Sachs has upped its game to criminal felony charges leveled by the U.S. Department of Justice in the 1MDB bribery case. The Justice Department released this statement on October 22, 2020 in conjunction with bringing the charges against Goldman Sachs:
“Over a period of five years, Goldman Sachs participated in a sweeping international corruption scheme, conspiring to avail itself of more than $1.6 billion in bribes to multiple high-level government officials across several countries so that the company could reap hundreds of millions of dollars in fees, all to the detriment of the people of Malaysia and the reputation of American financial institutions operating abroad. Today’s resolution, which includes a criminal guilty plea by Goldman Sachs’ subsidiary in Malaysia, demonstrates that the department will hold accountable any institution that violates U.S. law anywhere in the world by unfairly tilting the scales through corrupt practices.”
The message here is simple, if you’re a company with a good reputation, you need to do a proper and thorough amount of due diligence before you align your name and reputation with another company.
Hundreds of complaints filed with the Consumer Financial Protection Bureau (CFPB) by consumers using the Apple credit card that is provided by Goldman Sachs. The Apple credit card holders are alleging being put through a living hell by Goldman Sachs when fraudulent charges are made on their Apple credit card and a host of other problems.
In typical Goldman Sachs style, it has managed to earn the hostility of everyday consumers, airline pilots, and even a police officer with its handling of credit card complaints. Unfortunately for Apple, its name and reputation are being taking along for the ride – which raises the question, what marketing zombie at Apple didn’t see this coming when he decided to entangle Apple’s brand with “a great vampire squid wrapped around the face of humanity, relentlessly jamming its blood funnel into anything that smells like money,” as Matt Taibbi famously described Goldman Sachs at Rolling Stone.
The complaints at the CFPB aren’t helping the J.D. Power brand either. J.D. Power had announced in August of 2021 that the Apple credit card provided through Goldman Sachs had ranked number one in customer satisfaction in the midsize credit card segment. Goldman Sachs’ Chairman of Consumer Business, Harit Talwar, had gushed as follows about the award:
“Nothing energizes us more than the affirmation that we are providing a simple, transparent product that delivers value and that customers love. Creating this experience with Apple has been incredibly rewarding, and we are committed to continuing to deliver best-in-class service to our customers. It takes a village, and I am grateful to my colleagues at Goldman Sachs, the teams at Apple, and all of our partners who have helped us be No. 1 in customer satisfaction in the U.S. credit card industry.”
But in the very same month of August 2021, as Goldman was celebrating its J.D. Power award, egregious complaints were being filed with the CFPB. Here’s a sampling: (the redacted information has been done by the CFPB; typos are in the original):
A customer in California wrote this:
“This problem has been ongoing since XXXX, I have had to open multiple disputes through Apple credit card (goldman Sachs) and every time I open disputes, they ALWAYS favor the merchant ( XXXX ) There were multiple unauthorized purchases on my card through XXXX, XXXX helped with most of them besides one order that was {$1400.00}. My credit card issuer Goldman Sachs is saying that the dispute keeps favoring them no matter what evidence I give them. I really want to sue or something, I have no idea what to do now…” (Read the full complaint here.)
A customer in Massachusetts told the CFPB this:
“My 11 year old computer died and I went online to apple.com to buy a replacement one. Their site advertises that you can get an Apple credit card with 0 % APR for the first 12 months and pay off the computer. When I tried to redeem that offer, their Goldman Sachs website came back and extended a {$2500.00} credit limit, which does not cover the cost of a computer on their site. I called in to get the limit increased to {$3200.00} because I make {$320000.00} a year and have a XXXX credit rating. When I called in, their representative told me the only way to request a credit limit increase to cover the cost of the computer was to accept the credit card offer and open an account. So I did. He told me the next day I had to call back to request a credit increase. There was no other way to get an increase on the application. I have just done that, and despite making a high salary, having zero credit debt and having an excellent credit score, Goldman Sachs / Apple has denied the application and not giving me a reason…” (Read the full complaint here.)
A resident of Virginia wrote this:
“On XX/XX/21, an unknown charge for {$840.00} was Pending on my Apple Card (Goldman Sachs), I submitted a dispute the same day and was told that, because the charge was still ‘pending’, they would monitor the charge and if the charge posted, the dispute process would start with no further action from me. If the charge did not post, it would just drop off of my account. Since then, I have made dozens of calls and chat sessions with Apple Card Support about this charge that posted to my account on XX/XX/21. On this date, I received a ‘provisional credit’ and exactly one minute later, the provisional credit was reversed. After many phone calls, I finally learned that the dispute that I repeatedly called about had been ruled in the merchant ‘s favor because, they stated, I ‘withdrew my dispute’ — this is a complete falsehood…” (Read the full complaint here.)
The Apple credit card via Goldman Sachs was only launched three years ago in August of 2019. Goldman wrote the following at the time:
“Goldman Sachs is the issuer of the card and is responsible for underwriting, customer service, the underlying platform and all matters related to regulatory compliance through Goldman Sachs Bank USA.”
For the credit card to have generated hundreds of complaints in such a short span of time is remarkable and is apparently why Goldman Sachs is now being investigated by the CFPB.
On Monday, Consumer Financial Protection Bureau (CFPB) the federal agency announced it was creating a public registry to help law enforcement, investors and the public check the history of repeat offenders in finance. The CFPB already offers consumers who have been victimized by a financial firm the ability to file a public complaint with the CFPB. The agency then quickly demands a written response from the alleged wrongdoer. Repeat offenders dislike the fact that these complaints go into a permanent database at the CFPB, which can be mined by the public, reporters, attorneys and prosecutors looking for patterns of fraud.
On Tuesday, the CFPB released a circular letting financial firms know that if they sneak deceptive and/or illegal terms into the fine print of their consumer contracts they risk getting an enforcement action from the CFPB. One example cited was the Truth in Lending Act, which prohibits fine print in mortgage contracts that purport to force homeowners into mandatory arbitration (claiming to remove the option of a court proceeding) to deal with a mortgage dispute.
TPST $2.95 about 17m float may get some love Thursday premarket.. in first-line treatment of hepatocellular carcinoma (HCC) in a premarket press release followed by a webcasted conference call with associated slide presentation on Thursday, June 20, 2024 at 8:30 a.
GOVX $2.13 off to $4s resistance .. Uncle Sam $343 million and $45 million funding . Shorts running for the hills still. Shares of GeoVax (NASDAQ:GOVX) shot up 50% in mid-afternoon trading Tuesday amid news that the US government plans to fund a Phase 2b study of the company's next-generation COVID-19 vaccine.
Under the agreement, BARDA will award GeoVax up to $45M for the manufacturing of clinical materials and support for the Phase 2b study. The government will also provide around $343M for a clinical research organization to conduct the clinical
Uncle Sam $343 million and $45 million funding . Shorts running for the hills still. Shares of GeoVax (NASDAQ:GOVX) shot up 50% in mid-afternoon trading Tuesday amid news that the US government plans to fund a Phase 2b study of the company's next-generation COVID-19 vaccine.
Under the agreement, BARDA will award GeoVax up to $45M for the manufacturing of clinical materials and support for the Phase 2b study. The government will also provide around $343M for a clinical research organization to conduct the clinical trial.
Currently, the FDA has approved two mRNA COVID-19 vaccines, Pfizer (PFE) and BioNTech’s (BNTX) Comirnaty and Moderna’s (MRNA) Spikevax.
GEO-CM04S1 is currently being evaluated in three ongoing Phase 2 clinical trials:
As a primary vaccine in immunocompromised patients (with hematologic cancers receiving cell transplants or CAR-T therapy). ClinicalTrials.gov Identifier: NCT04977024. A recent presentation of unpublished data from the open-label portion of the trial indicates that GEO-CM04S1 is highly immunogenic in these patients, inducing both antibody responses, including neutralizing antibodies, and T cell responses.
As a booster vaccine in immunocompromised patients with chronic lymphocytic leukemia (CLL), a recognized high-risk group for whom current mRNA vaccines and monoclonal antibody (MAb) therapies appear inadequate relative to providing protective immunity. ClinicalTrials.gov Identifier: NCT05672355.
As a booster vaccine for healthy patients who have previously received the Pfizer or Moderna mRNA vaccine. This trial was fully enrolled in September 2023 and final results are expected in Fourth Quarter 2024, reflecting a 12-month tracking of study patients. ClinicalTrials.gov Identifier: NCT04639466.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for solid tumor cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation Covid-19 vaccine targeting high-risk immunocompromised patient populations. Currently in three Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized Covid-19 vaccines are insufficient, and as a booster vaccine in patients with chronic lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable Covid-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information, visit our website: www.geovax.com.
in first-line treatment of hepatocellular carcinoma (HCC) in a premarket press release followed by a webcasted conference call with associated slide presentation on Thursday, June 20, 2024 at 8:30 a.m.
Pump time ready again at .40s low .50s about 10m Floater. March pump $15 + lol newer ipo
NXL $1.42 + 72% hit 1.60s mental health stimulus device now approved in Brazil
VLCN Out of play now nice move
SILK NUWE SHMD
Silk Road Medical
26.76
+5.09
+23.49%
QLGN
Qualigen Therapeut.
0.210
+0.035
+20.26%
NUWE
Nuwellis Inc
0.221
+0.036
+19.62%
SHMD
SCHMID Group NV
4.09
+0.04
+0.99%
HOLO 1.14 52 week low added some maybe they let the goose loose and calm dilution soon